Intercept, Madrigal Get Ready For NASH Commercialization

 
• By Joseph Haas
  
Generate a summary of this article
Listen to this article
Beta

With a 22 June US FDA action date for obeticholic acid in non-alcoholic steatohepatitis, Intercept is thinking ahead to launch plans. Madrigal said it plans a Q2 filing for its NASH drug and hopes to find an ex-US commercial partner.

liver
Intercept, Madrigal may be heading toward approval in NASH

Intercept Pharmaceuticals, Inc. is getting ready once again – after a roughly three-year interruption – for commercialization of potentially the first approved non-alcoholic steatohepatitis (NASH) drug, as the user fee date for obeticholic acid (OCA) approaches. The company expects a US Food and Drug Administration advisory committee review of its new drug application a few weeks before the 22 June action date and told shareholders on 2 March that it thinks marketing of OCA in primary biliary cholangitis (PBC) will give it a head start on reaching the right clinicians in NASH.

Meanwhile, the other company with near-term likelihood of bringing a NASH drug to market in the US, Madrigal Pharmaceuticals,...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Strategy

More from Business

  • How A New Healthcare Dialogue Is Driving Market Access In Mexico

    Companies stand a better chance of securing public reimbursement in Mexico for innovative medicines if they understand changing approaches to healthcare. The shift means the emergence of managed entry agreements and a focus on economic impact, explains AMIIF, Mexico's research-based pharmaceutical industry association.

  • How Novartis Is Elevating CVD Outcomes, Driving ‘Personalized Access’ In APMA

    Novartis’s APMA chief outlines the company’s tailored approach to deliver long-term outcomes, novel access solutions via innovative financing options and shape the CVD disease ecosystem in the extraordinarily diverse region. Partnering to build AI infrastructure is another key prong.

  • India Rare Diseases: Court Shows Path For Policy Action, Funding, Price Issues-- Test-2

    A court order encompassing funding, drug pricing, clinical trials and overall policy implementation aspects is expected to bring about a paradigm shift in the treatment of rare diseases in India. Sarepta, Roche and Sanofi are among the key players that have been part of pricing discussions.